Effect of AP102, a subtype 2 and 5 specific somatostatin analog, on glucose metabolism in rats.

about

Effect of AP102, a subtype 2 and 5 specific somatostatin analog, on glucose metabolism in rats.

Item

http://www.wikidata.org/entity/Q54144943

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Effect of AP102, a subtype 2 a ...... on glucose metabolism in rats.

@en

Effect of AP102, a subtype 2 a ...... on glucose metabolism in rats.

@nl

type

Item

label

Effect of AP102, a subtype 2 a ...... on glucose metabolism in rats.

@en

Effect of AP102, a subtype 2 a ...... on glucose metabolism in rats.

@nl

prefLabel

Effect of AP102, a subtype 2 a ...... on glucose metabolism in rats.

@en

Effect of AP102, a subtype 2 a ...... on glucose metabolism in rats.

@nl

P1476

Effect of AP102, a subtype 2 a ...... on glucose metabolism in rats

@en

P2093

Alan G Harris

http://www.w3.org/2001/XMLSchema#string

Eric Grouzmann

http://www.w3.org/2001/XMLSchema#string

Erika Tarasco

http://www.w3.org/2001/XMLSchema#string

Petra Seebeck

http://www.w3.org/2001/XMLSchema#string

Svende Pfundstein

http://www.w3.org/2001/XMLSchema#string

Thomas A Lutz

http://www.w3.org/2001/XMLSchema#string

P2860

Acromegaly pathogenesis and treatment

Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly

Hyperglycemia induced by pasireotide in patients with Cushing's disease or acromegaly

Pasireotide in Acromegaly: An Overview of Current Mechanistic and Clinical Data.

Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis.

Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways.

Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal

Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.

Pasireotide (SOM230): development, mechanism of action and potential applications.

Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations.

P2888

s12020-017-1386-2

P304

124-133

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12020-017-1386-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Adrian F. Daly

Philippe J Eugster

Christina Neuner Boyle

P577

2017-08-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28822091

http://www.w3.org/2001/XMLSchema#string